Morgan Stanley Discount Zert COR .../ DE000ME86870 /
| 6/6/2024 9:05:32 PM | Chg.+1.68 | Bid10:00:34 PM | Ask10:00:34 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 208.39EUR | +0.81% | - Bid Size: - |
- Ask Size: - |
Cencora Inc | - USD | 12/31/2024 | Call |
GlobeNewswire
5/28
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire
5/15
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
5/13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
5/9
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
4/29
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire
4/17
2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire
3/22
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire
3/18
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire
2/14
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
1/23
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire
12/22/2023
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire
12/19/2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire
11/27/2023
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire
11/14/2023
Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
